Filing Flows › International Stem Cell (ISCO) › Q1 2025
International Stem Cell (ISCO) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 14, 2025
International Stem Cell (ISCO) reported revenue of $2.1M for the first quarter 2025 (Q1 2025), 0% from a year earlier and -13% from the quarter before. Operating margin was -10.1%, net loss $256K (12.0% of revenue).
International Stem Cell, Q1 2025: revenue $2.1M (0% year over year), operating margin -10.1%, net loss $256K, operating cash flow $227K. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.1M | -13% | 0% |
| Operating profit | −$215K | -522% | — |
| Net earnings | −$256K | -2427% | — |
| Operating cash flow | $227K | — | — |
| Free cash flow | $222K | — | — |
What changed
Revenue was $2.1M in Q1 2025, roughly flat year over year and down 13% from the previous quarter. Biomedical Market was the largest line at 94% of revenue.
Operating costs exceeded revenue by $215K, an operating margin of -10.1%. Total costs grew 2% against flat revenue. The fastest-growing cost line was Cost of revenue (+12%). The quarter ended with a net loss of $256K, after a profit of $11K the previous quarter.
Operating cash flow was $227K. Non-cash charges added back $55K of depreciation and amortization and $100K of share-based compensation. Working capital and other items added $328K. Capital expenditures of $5K left free cash flow of $222K.
Questions
What was International Stem Cell's revenue in the first quarter 2025?
International Stem Cell (ISCO) reported revenue of $2.1M for the first quarter 2025 (Q1 2025), 0% from a year earlier and -13% from the quarter before.
Was International Stem Cell profitable in the first quarter 2025?
Operating loss was $215K (-10.1% of revenue) and net loss $256K.